Volume 9, Issue 4 (11-2022)
JROS 2022, 9(4): 209-218 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ebrahimzadeh Babaki A, Ebrahimzadeh Babaki F, Mortazavizadeh M R. Survival Analysis of Osteosarcoma in a University Hospital in Yazd, Iran From 2004 to 2018: A Period Analysis. JROS 2022; 9 (4) :209-218
URL: http://jros.iums.ac.ir/article-1-2220-en.html
URL: http://jros.iums.ac.ir/article-1-2220-en.html
1- Department of Orthopedic, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
2- Department of Hematology-Oncology, Ali-ebn-Abitaleb Faculty of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran.
2- Department of Hematology-Oncology, Ali-ebn-Abitaleb Faculty of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran.
Abstract: (102 Views)
Background and Objectives: Osteosarcoma (OS) is the most common cause of limb loss due to cancers. This study determines the mean survival time in patients with OS and prognostic factors.
Methods: This retrospective study was conducted on patients with OS who were referred to Shah Vali Hospital, Yazd, Iran, from 2004 to 2018. The data on patient-related factors (age and sex), tumor-related factors (recurrence, recurrence site, and metastasis), and living status were obtained and analyzed.
Results: Overall, 29 patients were included, of which 21(72.4%) were male. The mean age of patients was 21.3±8.4 (age range of 8-42) years. The tumor site was the lower limb in 23 patients (79.3%), the upper limbs in 4 patients (13.8%), and the axial in 2 patients (6.9%). Meanwhile, 13(44.8%) patients died due to OS, and one (6.9%) died for other reasons. The mean survival time in the subjects was 83.1±14.71 months. The 1-year survival of patients was nearly 90%, 3-year survival was about 64%, and 5-year survival was 40%. Also, 7(24.1%) patients had primary metastasis. The mean survival period was 22.25 months in patients with primary metastasis and 98.87 months in patients without primary metastasis (P=0.011). Among the patients, 15(51.7%) had a recurrence, of which 6(20.7%) were local, and 9(31%) were distant recurrences. The mean survival period after the recurrence of patients was 21.27±5.07 months.
Conclusion: The mean survival period, according to sex, age, recurrence, and recurrence site, was not significant; however, it was significant according to metastasis.
Methods: This retrospective study was conducted on patients with OS who were referred to Shah Vali Hospital, Yazd, Iran, from 2004 to 2018. The data on patient-related factors (age and sex), tumor-related factors (recurrence, recurrence site, and metastasis), and living status were obtained and analyzed.
Results: Overall, 29 patients were included, of which 21(72.4%) were male. The mean age of patients was 21.3±8.4 (age range of 8-42) years. The tumor site was the lower limb in 23 patients (79.3%), the upper limbs in 4 patients (13.8%), and the axial in 2 patients (6.9%). Meanwhile, 13(44.8%) patients died due to OS, and one (6.9%) died for other reasons. The mean survival time in the subjects was 83.1±14.71 months. The 1-year survival of patients was nearly 90%, 3-year survival was about 64%, and 5-year survival was 40%. Also, 7(24.1%) patients had primary metastasis. The mean survival period was 22.25 months in patients with primary metastasis and 98.87 months in patients without primary metastasis (P=0.011). Among the patients, 15(51.7%) had a recurrence, of which 6(20.7%) were local, and 9(31%) were distant recurrences. The mean survival period after the recurrence of patients was 21.27±5.07 months.
Conclusion: The mean survival period, according to sex, age, recurrence, and recurrence site, was not significant; however, it was significant according to metastasis.
Type of Study: Research Article |
Subject:
Tumor surgery
Received: 2022/03/25 | Accepted: 2022/04/29 | Published: 2022/11/1
Received: 2022/03/25 | Accepted: 2022/04/29 | Published: 2022/11/1
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
